By reviewing the current literature, the review will summarize the molecular interplay that occurs between HIPK2 and molecular pathways involved in colon cancer regression and response to therapies that could likely be exploited as a potential biomarker and therapeutic target in colon cancer therapy. This evidence concerns the gene HIPK2 and malignant colon neoplasm.